Join
Live feed
·
PRReleasevia Quantisnow
Sio Gene Therapies Inc. logo

Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 Gangliosidosis

ByQuantisnow·Wall Street's wire, on your screen.
SIOX· Sio Gene Therapies Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SIOX (Sio Gene Therapies Inc.) and more on Quantisnow.